MENU
+Compare
GANX
Stock ticker: NASDAQ
AS OF
Jul 22 closing price
Price
$1.62
Change
+$0.04 (+2.53%)
Capitalization
56.01M

GANX Gain Therapeutics Forecast, Technical & Fundamental Analysis

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology... Show more

GANX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for GANX with price predictions
Jul 22, 2025

GANX's Stochastic Oscillator is remaining in oversold zone for 3 days

The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where GANX advanced for three days, in of 205 cases, the price rose further within the following month. The odds of a continued upward trend are .

GANX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on July 17, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on GANX as a result. In of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for GANX turned negative on July 16, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at .

GANX moved below its 50-day moving average on July 15, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for GANX crossed bearishly below the 50-day moving average on June 17, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GANX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for GANX entered a downward trend on July 14, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. GANX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.690) is normal, around the industry mean (18.132). P/E Ratio (0.000) is within average values for comparable stocks, (58.972). GANX's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.463). Dividend Yield (0.000) settles around the average of (0.042) among similar stocks. P/S Ratio (625.000) is also within normal values, averaging (274.444).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GANX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
GANX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

GANX is expected to report earnings to rise 4.69% to -16 cents per share on August 07

Gain Therapeutics GANX Stock Earnings Reports
Q2'25
Est.
$-0.17
Q1'25
Beat
by $0.03
Q4'24
Beat
by $0.10
Q3'24
Beat
by $0.04
Q2'24
Missed
by $0.23
The last earnings report on May 14 showed earnings per share of -15 cents, beating the estimate of -18 cents. With 371.74K shares outstanding, the current market capitalization sits at 56.01M.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
4800 Montgomery Lane
Phone
+1 301 500-1556
Employees
32
Web
https://www.gaintherapeutics.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AVCRF0.070.01
+21.73%
Avricore Health Inc.
UBAB55.000.72
+1.33%
United Bancorporation of Alabama, Inc.
DWMNF33.78N/A
N/A
Dowa Holdings Co., Ltd.
NESRF10.77-0.03
-0.28%
Northern Star Resources Ltd
LUDG0.08N/A
-4.60%
Ludwig Enterprises, Inc.

GANX and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, GANX has been loosely correlated with COYA. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if GANX jumps, then COYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GANX
1D Price
Change %
GANX100%
+2.53%
COYA - GANX
34%
Loosely correlated
-1.56%
OCUL - GANX
33%
Poorly correlated
+0.30%
TPST - GANX
32%
Poorly correlated
-0.47%
MGTX - GANX
32%
Poorly correlated
-1.15%
KRRO - GANX
32%
Poorly correlated
+6.37%
More